Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $16 Million - $18.7 Million
-86,667 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$179.86 - $214.88 $16.1 Million - $19.3 Million
-89,739 Reduced 50.87%
86,667 $16 Million
Q2 2021

Aug 16, 2021

BUY
$170.47 - $211.93 $3.41 Million - $4.24 Million
20,000 Added 12.79%
176,406 $31.6 Million
Q1 2021

May 17, 2021

BUY
$153.94 - $174.85 $986,139 - $1.12 Million
6,406 Added 4.27%
156,406 $26.2 Million
Q4 2020

Feb 16, 2021

SELL
$101.87 - $151.79 $50 Million - $74.5 Million
-490,773 Reduced 76.59%
150,000 $22.8 Million
Q3 2020

Nov 16, 2020

BUY
$99.9 - $121.13 $2.08 Million - $2.52 Million
20,773 Added 3.35%
640,773 $64.7 Million
Q2 2020

Aug 14, 2020

BUY
$92.74 - $125.82 $5.91 Million - $8.02 Million
63,748 Added 11.46%
620,000 $75 Million
Q1 2020

May 15, 2020

BUY
$79.39 - $115.35 $1.2 Million - $1.74 Million
15,073 Added 2.79%
556,252 $52.7 Million
Q4 2019

Feb 14, 2020

BUY
$78.31 - $95.34 $5.57 Million - $6.79 Million
71,179 Added 15.14%
541,179 $47.7 Million
Q3 2019

Nov 15, 2019

BUY
$74.85 - $85.99 $35.2 Million - $40.4 Million
470,000 New
470,000 $37.5 Million
Q2 2019

Aug 14, 2019

SELL
$76.06 - $120.81 $28.9 Million - $45.9 Million
-379,832 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$107.15 - $126.84 $3.11 Million - $3.68 Million
29,032 Added 8.28%
379,832 $44.6 Million
Q4 2018

Feb 15, 2019

BUY
$101.4 - $128.73 $5.15 Million - $6.54 Million
50,800 Added 16.93%
350,800 $38.2 Million
Q3 2018

Nov 14, 2018

BUY
$113.81 - $129.46 $14.8 Million - $16.9 Million
130,361 Added 76.85%
300,000 $38.4 Million
Q2 2018

Aug 14, 2018

BUY
$101.14 - $118.31 $17.2 Million - $20.1 Million
169,639 New
169,639 $19.2 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.